213 related articles for article (PubMed ID: 31981082)
1. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
[TBL] [Abstract][Full Text] [Related]
2. Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.
Pham P; Cheng C; Wu E; Kim I; Zhang R; Ma Y; Kortepeter CM; Muñoz MA
Pharmaceut Med; 2021 Sep; 35(5):307-316. PubMed ID: 34476768
[TBL] [Abstract][Full Text] [Related]
3. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
Phan M; Cheng C; Dang V; Wu E; Muñoz MA
Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
[TBL] [Abstract][Full Text] [Related]
5. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
[TBL] [Abstract][Full Text] [Related]
6. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
Harinstein L; Kalra D; Kortepeter CM; Muñoz MA; Wu E; Dal Pan GJ
Drug Saf; 2019 May; 42(5):649-655. PubMed ID: 30569267
[TBL] [Abstract][Full Text] [Related]
10. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
[TBL] [Abstract][Full Text] [Related]
11. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
13. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
14. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
[TBL] [Abstract][Full Text] [Related]
15. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
[TBL] [Abstract][Full Text] [Related]
16. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
Moore TJ; Furberg CD; Mattison DR; Cohen MR
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
[TBL] [Abstract][Full Text] [Related]
17. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
[TBL] [Abstract][Full Text] [Related]
20. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
